+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 30 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are studying the effectiveness, safety, and tolerability of combining elecoglipron and dapagliflozin compared to using each drug alone in adults with type 2 diabetes mellitus T2DM who are not well controlled by lifestyle changes or other diabetes medications. This phase III trial aims to understand how well these treatments manage blood sugar levels in this population. Participants will be randomly assigned to one of five groups two different doses of elecoglipron combined with dapagliflozin, two doses of elecoglipron combined with a placebo matching dapagliflozin, or dapagliflozin alone with a placebo matching elecoglipron. All medications are taken orally once daily. The study uses a double-blind, parallel-group design to compare these treatments over 40 weeks. During the study, participants will have their blood sugar control measured primarily by changes in Hemoglobin A1c HbA1c from the start to week 40. Secondary measures include body weight changes, fasting plasma glucose, blood pressure, and time to starting rescue medication. Regular assessments will monitor safety and treatment effects throughout the trial period, which lasts about 40 weeks.

Age: 18Years +All GendersPhase 3
303 locations
P

Actively Recruiting

Researchers are evaluating disitamab vedotin alone or combined with pembrolizumab to treat urothelial cancer that expresses HER2. This study focuses on participants with locally advanced or metastatic urothelial cancer that cannot be removed by surgery. It aims to assess how well the drug works and to monitor the side effects experienced by participants. Participants receive disitamab vedotin intravenously every 2 weeks, either alone or with pembrolizumab given by intravenous infusion on Day 1 of each 6-week cycle. The study includes multiple cohorts receiving different combinations or monotherapy treatments. The treatment period and monitoring last approximately 2 years, with ongoing assessments of drug effects and safety. During the study, participants undergo regular evaluations including imaging scans to measure tumor response, laboratory tests, electrocardiograms to monitor heart function, and assessments of side effects. Researchers measure treatment response using established cancer evaluation criteria and track survival and disease control over about 3 years. Participants are closely monitored for adverse effects and blood levels of the drugs to understand how the treatments behave in the body.

Age: 18Years +All GendersPhase 2
221 locations
A

Actively Recruiting

Researchers are evaluating whether combining tucatinib with trastuzumab and mFOLFOX6 works better than standard treatments for people with HER2 positive colorectal cancer that has spread or cannot be removed by surgery. This Phase 3 study also aims to learn about the side effects that may occur when taking this combination of drugs. Participants have metastatic or unresectable colorectal cancer and are randomly assigned to different treatment groups. Participants are randomly placed in one of two study groups. One group receives tucatinib taken orally twice daily along with trastuzumab given intravenously every 3 weeks and mFOLFOX6 chemotherapy every 2 weeks. The other group receives standard care, which may be mFOLFOX6 alone or combined with bevacizumab or cetuximab, both given intravenously on different schedules. Tissue samples and biopsies are collected before treatment to confirm HER2 positivity and other markers. During the study, participants will have regular evaluations including imaging scans to measure cancer progression, blood tests, and assessments of side effects and quality of life. Progression-free survival is the primary outcome measured for up to about 3 years, with other outcomes like overall survival and response rate also tracked. Safety monitoring continues for about one year after the last treatment. The study lasts several years, with ongoing follow-up to understand long-term effects and benefits.

Age: 18Years +All GendersPhase 3
366 locations
P

Actively Recruiting

Healthy Volunteer

Researchers are evaluating two dose levels of mRNA-1283 in children aged 6 months to less than 12 years to find the best dose for each age group. The study is a phase 2, randomized, observer-blind trial comparing mRNA-1283 with mRNA-1273 as an active comparator. It aims to assess safety, immune response, and side effects related to these vaccines against SARS-CoV-2. The study includes two cohorts Cohort 1 involves children aged 2 to less than 12 years receiving a single intramuscular dose of either mRNA-1283 at Dose Level 1 or Dose Level 2, or mRNA-1273. Cohort 2 includes children aged 6 months to less than 2 years who are unvaccinated against COVID-19 and receive two intramuscular doses 28 days apart of either mRNA-1283 at Dose Level 1 or Dose Level 2, or mRNA-1273. The study compares the immune responses and side effects between these groups. Participants will be monitored for local and systemic adverse reactions for 7 days after vaccination and unsolicited adverse events for up to 28 days. Serious and medically attended adverse events will be tracked throughout the study, which lasts up to 13 months. Researchers will measure antibody levels against SARS-CoV-2 at specific visits to evaluate immune response. The trial includes regular medical evaluations and safety assessments to ensure participant well-being.

Age: 6Months - 11YearsAll GendersPhase 2
31 locations
E

Actively Recruiting

Healthy Volunteer

Researchers are studying the effectiveness, safety, and tolerability of a vaccine against Clostridioides difficile C. difficile infection in adults aged 65 years and older. The study aims to reduce the number of C. difficile infections, a serious cause of diarrhea, by comparing the vaccine to a placebo. This is a phase 3, randomized, double-blinded trial sponsored by Pfizer. Participants will receive either the C. difficile vaccine or a saline placebo, both given as shots into the upper arm muscle. The study duration varies based on the occurrence of diarrhea events related to C. difficile infection, lasting up to about three and a half years. The study may end earlier if sufficient data is collected or if the vaccine is found ineffective. Vaccination involves two doses, and participants will be closely monitored during and after vaccination. During the study, participants will have three planned clinic visits and three phone visits, followed by annual clinic visits until the study ends. If participants have three or more loose stools in 24 hours, they must save the next stool and contact the study site for infection assessment, which can occur in person or remotely. Researchers will track local and systemic reactions, adverse events, and the incidence of C. difficile infections as primary outcomes over the study period.

Age: 65Years +All GendersPhase 3
185 locations
E

Actively Recruiting

Researchers are evaluating how well the 20-valent pneumococcal conjugate vaccine 20vPnC works against pneumonia caused by seven new types of the Streptococcus pneumoniae bacteria. This study focuses on adults aged 65 years and older who are hospitalized with pneumonia confirmed by chest imaging. The study aims to compare the presence of pneumonia caused by these specific bacteria types in people vaccinated with 20vPnC versus those with pneumonia caused by other bacteria or strains. This observational study involves adults 65 years and older hospitalized with radiologically-confirmed community-acquired pneumonia RADCAP. Participants will provide a urine sample for testing pneumococcal bacteria using BinaxNOW and specific urinary antigen detection assays UAD-1 and UAD-2. Cases are identified by detection of the seven additional bacteria types in 20vPnC beyond the previous 13-valent vaccine, while controls include other pneumonia cases without these serotypes. No treatment is given as part of the study. Participants will be involved for about 1 to 2 days for urine sample collection and providing medical history. Researchers will collect detailed information on illness and hospital stay up to 30 days through medical record review. The main outcome measured is the effectiveness of 20vPnC against pneumonia caused by the seven additional bacterial types over approximately 55 months. Other clinical features and pneumonia types will also be reviewed during this period.

Age: 65Years +All Genders
54 locations
S

Actively Recruiting

Researchers are evaluating whether adding nivolumab to the usual treatment of paclitaxel and ramucirumab improves outcomes for patients with advanced gastric or esophageal adenocarcinoma that has spread locally or to distant sites. This phase IIIII trial aims to compare progression-free survival and overall survival between the combination including nivolumab and the standard regimen without it. The study also assesses response rates, disease control, safety, and quality of life measures to understand the impact of this treatment approach. Participants are randomly assigned to one of two treatment groups. One group receives nivolumab intravenously on day 1, ramucirumab intravenously on days 1 and 15, and paclitaxel intravenously on days 1, 8, and 15 of each 28-day cycle. The other group receives ramucirumab and paclitaxel on the same schedule without nivolumab. Treatment cycles continue every 28 days unless the disease progresses or unacceptable side effects occur. Imaging scans including CT and MRI are performed regularly throughout the study, and optional blood samples may be collected. During the trial, participants undergo assessments including imaging scans and quality of life questionnaires. Follow-up visits occur at 30, 60, and 90 days after treatment ends, then every six months for up to three years. Researchers measure outcomes such as progression-free survival, overall survival, response rates, disease control, and adverse events. Patient-reported symptoms and health-related quality of life are also evaluated to monitor treatment effects and tolerability over time.

Age: 18Years +All GendersPhase 2Phase 3
378 locations
R

Actively Recruiting

Researchers are evaluating the addition of cemiplimab, an immunotherapy drug that blocks the PD-1 pathway to help the immune system attack tumor cells, to the usual treatment of docetaxel and ramucirumab for patients with stage IV or recurrent non-small cell lung cancer NSCLC who have previously been treated with platinum chemotherapy and immunotherapy. This phase IIIII randomized trial aims to compare overall survival and other outcomes between the two treatment approaches, including progression-free survival, response rates, and safety. Participants are randomly assigned to one of two groups. One group receives dexamethasone orally, ramucirumab intravenously, and docetaxel intravenously every 21 days. The other group receives the same treatment plus cemiplimab intravenously every 21 days. Treatment cycles continue as long as there is no disease progression or unacceptable side effects. Throughout the study, participants have blood samples collected and undergo CT or MRI scans to monitor disease status. During the study, participants will have regular assessments including tumor imaging and blood tests to track treatment effects and side effects. After completing treatment, participants are followed every 3 to 6 months for up to 3 years to monitor overall survival and disease progression. The study also collects samples for future research on tumor DNA. Total participation can last several years including treatment and follow-up periods.

Age: 18Years +All GendersPhase 2Phase 3
413 locations
E

Actively Recruiting

Researchers are evaluating how to best recommend chemotherapy for patients with colon cancer based on the presence or absence of circulating tumor DNA ctDNA after surgery. This Phase IIIII trial aims to determine if ctDNA can be used to better identify patients who need adjuvant chemotherapy and to assess optimal chemotherapy regimens for those with detectable ctDNA, as current biomarkers have not been prospectively validated. Participants are assigned to different groups based on their ctDNA status after surgery. Those without detectable ctDNA may undergo serial ctDNA monitoring without treatment or receive shorter chemotherapy regimens. Patients with detectable ctDNA receive more intensive chemotherapy options, including combinations of oxaliplatin, leucovorin, 5-fluorouracil, irinotecan, or capecitabine, administered intravenously or orally over cycles lasting several weeks. The study includes randomization and uses the Signatera test for central ctDNA detection. During the study, participants will undergo regular blood tests for ctDNA status, imaging scans, and clinical assessments. Researchers will track ctDNA positivity over up to 3 years and disease-free survival over up to 5 years. Other measures include overall survival, recurrence rates, and chemotherapy compliance. The total study duration may extend several years with ongoing monitoring to evaluate safety and treatment outcomes.

Age: 18Years +All GendersPhase 2Phase 3
1085 locations
P

Actively Recruiting

Researchers are evaluating combinations of targeted drugs in people with advanced non-small cell lung cancer that has spread and shows specific changes in the EGFR and MET genes. This phase II Lung-MAP trial focuses on patients whose cancer has progressed after treatment with osimertinib and aims to compare the effectiveness of combining capmatinib, osimertinib, and ramucirumab. The study also investigates safety, response rates, and survival outcomes while collecting biological samples for further analysis. Participants are randomly assigned to one of two groups. One group receives capmatinib and osimertinib as oral medications plus ramucirumab given intravenously, while the other group receives only capmatinib and osimertinib orally. During the trial, patients undergo regular CT or MRI scans and blood sample collections to monitor their disease and treatment effects. The study includes detailed assessments of tumor responses and side effects over time. Throughout the trial, participants will have scans and blood tests at scheduled intervals to assess disease progression and treatment impact. Researchers will monitor progression-free survival as the main outcome, along with response duration and toxicity. Blood samples are also collected to study circulating tumor DNA. The study continues up to three years, with ongoing safety and efficacy evaluations. Participants must meet specific health criteria and provide informed consent before joining.

Age: 18Years +All GendersPhase 2
454 locations

1-10 of 30

1